{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:13:52Z","timestamp":1792721632484,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jaci.2024.02.017","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:23:22Z","timestamp":1709810602000},"page":"1611-1620.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy"],"prefix":"10.1016","volume":"153","author":[{"given":"Tarun","family":"Keswani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"LaHood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlee","family":"Marini-Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijoya","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na","family":"Andrieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny L.","family":"Sneed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars C.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-2286","authenticated-orcid":false,"given":"Sarita U.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.02.017_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5630","article-title":"Prevalence and severity of food allergies among US adults","volume":"2","author":"Gupta","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2024.02.017_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.anai.2022.12.031","article-title":"The epidemiology of multifood allergy in the United States: a population-based study","volume":"130","author":"Warren","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10322","key":"10.1016\/j.jaci.2024.02.017_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.02.017_bib4","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaci.2019.07.028","article-title":"Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy","volume":"144","author":"Patil","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164501","article-title":"Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy","volume":"133","author":"LaHood","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.02.017_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaci.2015.03.026","article-title":"Peanut oral immunotherapy transiently expands circulating Ara h 2\u2013specific B cells with a homologous repertoire in unrelated subjects","volume":"136","author":"Patil","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaci.2013.11.007","article-title":"Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy","volume":"133","author":"Vickery","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaci.2020.03.035","article-title":"Biomarkers of severity and threshold of allergic reactions during oral peanut challenges","volume":"146","author":"Santos","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2014.09.001","article-title":"Distinct parameters of the basophil activation test reflect the severity and threshold of allergic reactions to peanut","volume":"135","author":"Santos","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2014.04.039","article-title":"Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children","volume":"134","author":"Santos","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib11","article-title":"High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy","volume":"2","author":"Chen","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jaci.2024.02.017_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jaci.2005.06.033","article-title":"IgE and IgG4 epitope mapping by microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h 2","volume":"116","author":"Shreffler","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2012.10.048","article-title":"Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens","volume":"131","author":"Vickery","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaci.2007.11.039","article-title":"Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy","volume":"121","author":"Flinterman","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaci.2023.01.005","article-title":"The role of IgG","volume":"151","author":"Strobl","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41577-022-00786-1","article-title":"Allergen immunotherapy: past, present and future","volume":"23","author":"Durham","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaci.2021.01.030","article-title":"Evolution of epitope-specific IgE and IgG","volume":"148","author":"Suarez-Farinas","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/cea.14433","article-title":"Design of an Ara h 2 hypoallergen from conformational epitopes","volume":"54","author":"Min","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.02.017_bib19","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4049\/jimmunol.157.4.1645","article-title":"Anaphylaxis mediated through a humanized high affinity IgE receptor","volume":"157","author":"Dombrowicz","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1084\/jem.20142182","article-title":"A single glycan on IgE is indispensable for initiation of anaphylaxis","volume":"212","author":"Shade","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2024.02.017_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2010.12.1111","article-title":"A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response","volume":"127","author":"Varshney","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"10207","key":"10.1016\/j.jaci.2024.02.017_bib22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.02.017_bib23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jaci.2016.08.017","article-title":"Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults","volume":"139","author":"Jones","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2013.12.1037","article-title":"Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)","volume":"133","author":"Syed","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib25","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa1514209","article-title":"Effect of avoidance on peanut allergy after early peanut consumption","volume":"374","author":"Du Toit","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.02.017_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaci.2017.12.979","article-title":"Immune mechanisms of oral immunotherapy","volume":"141","author":"Kulis","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.02.017_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam9171","article-title":"A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders","volume":"9","author":"Wambre","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2024.02.017_bib28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/all.15601","article-title":"IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases","volume":"78","author":"Aranda","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.02.017_bib29","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/all.14905","article-title":"Accurate and reproducible diagnosis of peanut allergy using epitope mapping","volume":"76","author":"Su\u00e1rez-Fari\u00f1as","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.02.017_bib30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/all.15659","article-title":"Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice","volume":"78","author":"Paolucci","year":"2023","journal-title":"Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924002331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924002331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T16:57:47Z","timestamp":1736182667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924002331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0091674924002331"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.02.017","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}